Orphan drugs: The regulatory environment

Drug Discovery Today

Volumn 18, Issue 3-4, 2013, Pages 163-172

  Franco, Pedro ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

AUSTRALIA; CANADA; DRUG LEGISLATION; EUROPEAN UNION; HEALTH CARE POLICY; HUMAN; JAPAN; RARE DISEASE; REVIEW; SINGAPORE; TAIWAN; UNITED STATES;

AUSTRALIA; CANADA; DRUG INDUSTRY; EUROPEAN UNION; JAPAN; LEGISLATION, DRUG; MOTIVATION; ORPHAN DRUG PRODUCTION; SINGAPORE; TAIWAN; UNITED STATES;

EID: 84873079257     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.08.009     Document Type: Review

References (42)

1. L. Williams Stedman's medical dictionary 2006 Lippincott Williams & Wilkins
2. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe's challenges no SEC-2008-2713 11 November 2008
3. R. Joppi Orphan drug development is not taking off Br. J. Clin. Pharmacol. 67 2009 494 502
4. E. Tambuyzer Rare diseases, orphan drugs and their regulation: questions and misconceptions Nat. Rev. Drug. Discov. 9 2010 921 929
5. J.K. Aronsom Rare diseases and orphan drugs Br. J. Clin. Pharmacol. 61 2006 243 245
6. Council recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02)
7. G. Randhawa Orphan Diseases and Drugs-Widen the Horizon 2009 Verband Forschender Arzneimittelhersteller E.V
8. Regulation (EC) No. 141/2000 of the European Parliament and Council of 16 December 1999
9. Orphan drug Act, Public Law 97-414, 4 January 1983 (US)
10. Orphan Drug amendments of 1985, Public Law 99, 91, 15 August 1985 (US)
11. Orphan Drug amendments of 1988, Public Law 100-290, 18 April 1988 (US)
12. The Pharmaceutical Affair Law 145-10 August 1960-Revised in 1993 (Japan)
13. Therapeutic Goods Regulations 1990 (Statutory Rules 1990) No. 394 (Australian)
14. D.M. Michols Report on orphan drug policy for Canada 1997 Health Canada
15. Singapore Medicines Act (Chapter 176-section 9) Medicines (Orphan drugs), 04 November 1991 (Singapore)
16. Council Recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02)
17. I. Melnikova Rare diseases and orphan Nat. Rev. Drug Discov. 11 2012 267 268
18. M.M. Braun Emergence of orphan drugs in the United States: a quantitative assessmnet of the first 25 years Nat. Rev. Drug Discov. 9 2010 519 522
19. S. Villa Orphan drug legislation: lessons for neglected tropical diseases Int. J. Health Plan. Manage. 24 2008 27 42
20. M. Narukawa Japanese approach to orphan drugs Pharm. Policy Law 3 2001 41 42
21. S. Shorthose Guide to EU Pharmaceutical Regulatory Law 2010 Walters Kluwes
22. A. Sharma Orphan drug: development trends and strategies J. Pharm. Bioallied Sci. 2:4 2010 290 299
23. M. Mathieu New Drug Approval in the United States 2002 Parexel
24. P.J. Berry, and P. Takes Fundamentals of US Regulatory Affairs 2009 Regulatory Affairs Professionals Society
25. Regulation (EC) No. 847/2000 of the European Parliament and Council of 27 April 2000
26. Posada de la Paz Diseases Epidemiology 2010 Springer
27. Communication from the Commission: Guideline on aspects of the application of Article 8(2) of Regulation (EC) No 141/2000: review of the period of market exclusivity of orphan medicinal products-C (2008) 4051-17 September 2008
28. K. Westermark The regulation of orphan medicines in the EU: objectives reached and main challenges when facing the future Pharm. Policy Law 9 2007 327 342
29. E. Seoane-Vazquez Incentives for orphan drug research and development in the United States Orphanet. J. Rare Diss. 3 2008 1 7
30. A.R. Pariser Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials Discov. Med. 11 2011 367 375
31. S.M. Muller, and J. Llinares-Garcia Clinical Pharmacology: Current Topics and Case Studies 2010 Springer
32. C. Schey Estimating the budget impact of orphan medicines in Europe: 2010-2020 Orphanet. J. Rare Dis. 6 2011 1 10
33. K. Westermark European regulation on orphan medicinal products: 10 years of experiences and future perspectives Nat. Rev. Drug Discov. 10 2011 341 349
34. R. Hyde, and D. Dobrovolny Orphan drug pricing and payer management in the United States: are we approaching the tipping point? Am Health Drug Benefit 5 2012 1 6
35. E. Cooke The European regulation on orphan medicinal products Pharm. Policy Law 3 2001 11 18
36. J. Torrent-Farnell, and R. Morros The EU challenges on the designation of orphan medicinal products Pharm. Policy Law 3 2001 19 35
37. EMA Information on Procedure for orphan medicinal product designation-general principles (2009)-EMA/710915/2009-Rev. 5
38. Regulation (EC) No. 726/2004 of the European Parliament and Council of 31 March 2004
39. Guideline on the format and content of applications for designation as orphan medicinal products and on the transfer of designation from one sponsor to another, Commission guideline (2007) ENTR/6283/00
40. EC (2005) Marketing Authorisation, Notice to Applicants, Vol. 2A, European Commission
41. P. Le Courtois, and M. Carr Orphan medicinal products-the role of the EMEA Pharm. Policy Law 3 2001 31 35
42. Communication from the Commission on Regulation (EC) No 141/200 of the European Parliament and of the Council on orphan medicinal products-(2003/C 178/02)-29 July 2003